Swedish biotech firm Denator said this week it has completed its sixth financing round, securing €2.75 million ($3.66 million) in funding.

According to a statement by Denator CEO Olof Skold, the funds will be used to continue market expansion and development of the firm's heat-stabilization technology, which uses rapid heating as opposed to conventional snap-freezing to halt enzyme activity in biological samples, thus preserving them for analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.